Details of the Drug

General Information of Drug (ID: DMHNQOG)

Drug Name
Zafirlukast
Synonyms
Accolate; Accoleit; Aeronix; Olmoran; Respix; Zafirst; AstraZeneca brand of zafirlukast; Menarini brand of zafirlukast; Novartis brand of zafirlukast; Zeneca brand of zafirkulast; Accolate (TN); Accoleit (TN); Vanticon (TN); Zafirlukast [USAN:BAN:INN]; Accolate, Accoleit, Vanticon, Zafirlukast; Zafirlukast (JAN/USAN/INN); Cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; Cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; Cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; Cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Approved [1], [2]
Therapeutic Class
Antiasthmatic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 575.7
Topological Polar Surface Area (xlogp) 5.5
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The apparent oral clearance of drug is 20 L/h [4]
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 10 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.9926 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 70 L [4]
Chemical Identifiers
Formula
C31H33N3O6S
IUPAC Name
cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate
Canonical SMILES
CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
InChI
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
InChIKey
YEEZWCHGZNKEEK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5717
ChEBI ID
CHEBI:10100
CAS Number
107753-78-6
DrugBank ID
DB00549
TTD ID
D05DVP
VARIDT ID
DR00872
INTEDE ID
DR1723
ACDINA ID
D00737

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukotriene CysLT1 receptor (CYSLTR1) TTGKOY9 CLTR1_HUMAN Antagonist [8], [9], [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [12]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Leukotriene CysLT1 receptor (CYSLTR1) DTT CYSLTR1 1.96E-02 0.24 0.43
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.93E-03 -2.19E-01 -4.49E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.25E-03 -4.98E-01 -6.49E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.90E-01 2.35E-02 7.88E-02
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 5.11E-09 5.07E-01 9.56E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Zafirlukast
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Budesonide DMJIBAW Moderate Decreased metabolism of Zafirlukast caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [49]
Coadministration of a Drug Treating the Disease Different from Zafirlukast (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Decreased metabolism of Zafirlukast caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [50]
Nateglinide DMLK2QH Moderate Decreased metabolism of Zafirlukast caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [51]
Midostaurin DMI6E0R Moderate Decreased metabolism of Zafirlukast caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [52]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Zafirlukast caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [53]
Donepezil DMIYG7Z Minor Decreased metabolism of Zafirlukast caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [54]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Zafirlukast caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [55]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [56]
Cilostazol DMZMSCT Moderate Decreased metabolism of Zafirlukast caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [57]
Voriconazole DMAOL2S Moderate Decreased metabolism of Zafirlukast caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [58]
Cariprazine DMJYDVK Moderate Decreased metabolism of Zafirlukast caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [53]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Zafirlukast and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [59]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Zafirlukast caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Tucatinib DMBESUA Moderate Decreased metabolism of Zafirlukast caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Alpelisib DMEXMYK Moderate Increased metabolism of Zafirlukast caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Bosutinib DMTI8YE Moderate Decreased metabolism of Zafirlukast caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [53]
Anisindione DM2C48U Moderate Decreased metabolism of Zafirlukast caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [63]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Zafirlukast caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [64]
Ulipristal DMBNI20 Minor Decreased metabolism of Zafirlukast caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [53]
Alfentanil DMVO0UB Moderate Decreased metabolism of Zafirlukast caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [65]
Mifepristone DMGZQEF Moderate Decreased metabolism of Zafirlukast caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [66]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Zafirlukast caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [53]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Zafirlukast caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [67]
Aprepitant DM053KT Moderate Increased metabolism of Zafirlukast caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [68]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Zafirlukast caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [69]
Escitalopram DMFK9HG Minor Decreased metabolism of Zafirlukast caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [70]
Ospemifene DMC4GEI Moderate Decreased metabolism of Zafirlukast caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [71]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Zafirlukast caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [72]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Cannabidiol. Epileptic encephalopathy [8A62] [53]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Zafirlukast caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [73]
Solifenacin DMG592Q Moderate Decreased metabolism of Zafirlukast caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [74]
Mirabegron DMS1GYT Minor Decreased metabolism of Zafirlukast caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [75]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Zafirlukast caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [76]
Ripretinib DM958QB Moderate Decreased metabolism of Zafirlukast caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [58]
Avapritinib DMK2GZX Moderate Decreased metabolism of Zafirlukast caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [53]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Zafirlukast caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [77]
Rifapentine DMCHV4I Moderate Increased metabolism of Zafirlukast caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [78]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Brentuximab vedotin. Hodgkin lymphoma [2B30] [79]
MK-1439 DM215WE Minor Decreased metabolism of Zafirlukast caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [80]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [81]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Zafirlukast and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [82]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Zafirlukast caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Amprenavir DMLMXE0 Minor Decreased metabolism of Zafirlukast caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Atazanavir DMSYRBX Moderate Decreased metabolism of Zafirlukast caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Maraviroc DMTL94F Moderate Decreased metabolism of Zafirlukast caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Zafirlukast caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [58]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Zafirlukast and Mipomersen. Hyper-lipoproteinaemia [5C80] [86]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Zafirlukast and Teriflunomide. Hyper-lipoproteinaemia [5C80] [64]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Zafirlukast and BMS-201038. Hyper-lipoproteinaemia [5C80] [87]
Retapamulin DM9JXB7 Minor Decreased metabolism of Zafirlukast caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [88]
Lesinurad DMUR64T Moderate Decreased metabolism of Zafirlukast caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [89]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Zafirlukast caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [90]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Methotrexate. Leukaemia [2A60-2B33] [53]
Pemigatinib DM819JF Moderate Decreased metabolism of Zafirlukast caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [53]
Brigatinib DM7W94S Moderate Decreased metabolism of Zafirlukast caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [58]
Ceritinib DMB920Z Moderate Decreased metabolism of Zafirlukast caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [91]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Zafirlukast caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [92]
PF-06463922 DMKM7EW Moderate Decreased metabolism of Zafirlukast caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [93]
Osimertinib DMRJLAT Moderate Decreased metabolism of Zafirlukast caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [94]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Zafirlukast caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [95]
Selpercatinib DMZR15V Moderate Decreased metabolism of Zafirlukast caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [53]
Halofantrine DMOMK1V Major Decreased metabolism of Zafirlukast caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [96]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [97]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Idelalisib. Mature B-cell leukaemia [2A82] [98]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Zafirlukast caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [58]
IPI-145 DMWA24P Moderate Decreased metabolism of Zafirlukast caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [99]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Zafirlukast caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [100]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Clofarabine. Mature B-cell lymphoma [2A85] [101]
Selumetinib DMC7W6R Moderate Decreased metabolism of Zafirlukast caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [102]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Zafirlukast caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [53]
Ubrogepant DM749I3 Moderate Decreased metabolism of Zafirlukast caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [103]
Flibanserin DM70DTN Moderate Decreased metabolism of Zafirlukast caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [104]
Panobinostat DM58WKG Moderate Decreased metabolism of Zafirlukast caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [105]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Zafirlukast and Thalidomide. Multiple myeloma [2A83] [82]
Nilotinib DM7HXWT Moderate Decreased metabolism of Zafirlukast caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [106]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Zafirlukast caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [53]
Imatinib DM7RJXL Moderate Decreased metabolism of Zafirlukast caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [107]
Modafinil DMYILBE Minor Decreased metabolism of Zafirlukast caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [58]
Entrectinib DMMPTLH Moderate Decreased metabolism of Zafirlukast caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [108]
Sibutramine DMFJTDI Minor Decreased metabolism of Zafirlukast caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [109]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Zafirlukast caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [110]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Zafirlukast caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [111]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Zafirlukast caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [112]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Zafirlukast caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [113]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Zafirlukast caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [114]
Lefamulin DME6G97 Moderate Decreased metabolism of Zafirlukast caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [115]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Zafirlukast caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [116]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Zafirlukast caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [117]
Enzalutamide DMGL19D Moderate Decreased metabolism of Zafirlukast caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [118]
Silodosin DMJSBT6 Moderate Decreased metabolism of Zafirlukast caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [119]
Bosentan DMIOGBU Moderate Increased metabolism of Zafirlukast caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [120]
Everolimus DM8X2EH Moderate Decreased metabolism of Zafirlukast caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [121]
Axitinib DMGVH6N Moderate Decreased metabolism of Zafirlukast caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [53]
Temsirolimus DMS104F Moderate Decreased metabolism of Zafirlukast caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [122]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Zafirlukast and Leflunomide. Rheumatoid arthritis [FA20] [64]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Zafirlukast caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [123]
Pimozide DMW83TP Major Decreased metabolism of Zafirlukast caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [58]
Fentanyl DM8WAHT Major Decreased metabolism of Zafirlukast caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [124]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Zafirlukast caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [125]
Vardenafil DMTBGW8 Moderate Decreased metabolism of Zafirlukast caused by Vardenafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [126]
LDE225 DMM9F25 Moderate Decreased metabolism of Zafirlukast caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [127]
Larotrectinib DM26CQR Moderate Decreased metabolism of Zafirlukast caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [58]
Docetaxel DMDI269 Moderate Decreased metabolism of Zafirlukast caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [128]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Zafirlukast caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [53]
Armodafinil DMGB035 Minor Decreased metabolism of Zafirlukast caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [58]
LEE011 DMMX75K Moderate Decreased metabolism of Zafirlukast caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [58]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Zafirlukast and Naltrexone. Substance abuse [6C40] [129]
Warfarin DMJYCVW Moderate Decreased metabolism of Zafirlukast caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [63]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Zafirlukast caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [130]
Clopidogrel DMOL54H Minor Decreased metabolism of Zafirlukast caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [131]
Saxagliptin DMGXENV Moderate Decreased metabolism of Zafirlukast caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [53]
⏷ Show the Full List of 110 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Zafirlukast 10 mg tablet 10 mg Oral Tablet Oral
Zafirlukast 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3322).
2 Role of antileukotriene agents in asthma therapy. J Am Osteopath Assoc. 2000 Jan;100(1):32, 37-43.
3 BDDCS applied to over 900 drugs
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
9 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
10 Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol. 2012 May;68(5):681-8.
11 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
12 Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
24 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
25 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
26 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
27 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
28 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
29 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
30 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
31 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
32 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
33 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
34 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
35 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
36 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
37 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
38 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
39 Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
40 Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
41 Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
42 Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48.
43 Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
44 The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
45 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
46 Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
47 Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
48 In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
49 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
50 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
51 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
52 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
53 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
54 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
55 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
56 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
57 Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
58 Cerner Multum, Inc. "Australian Product Information.".
59 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
60 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
61 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
62 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
63 Dekhuijzen PN, Koopmans PP "Pharmacokinetic profile of zafirlukast." Clin Pharmacokinet 41 (2002): 105-14. [PMID: 11888331]
64 Canadian Pharmacists Association.
65 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
66 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
67 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
68 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
69 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
70 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
71 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
72 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
73 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
74 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
75 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
76 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
77 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
78 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
79 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
80 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
81 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
82 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
83 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
84 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
85 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
86 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
87 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
88 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
89 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
90 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
91 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
92 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
93 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
94 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
95 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
96 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
97 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
98 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
99 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
100 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
101 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
102 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
103 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
104 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
105 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
106 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
107 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
108 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
109 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
110 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
111 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
112 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
113 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
114 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
115 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
116 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
117 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
118 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
119 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
120 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
121 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
122 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
123 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
124 Labroo RB, Paine MF, Thummel KE, Kharasch ED "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implicaitons for interindividual variability in disposition, efficacy, and drug interactions." Drug Metab Dispos 25 (1997): 1072-80. [PMID: 9311623]
125 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
126 Product Information. Levitra (vardenafil). Bayer, West Haven, CT.
127 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
128 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
129 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
130 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
131 Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.